• 1
    Abrams P, Wein AJ. Introduction. overactive bladder and its treatments. Urology 2000; 55 (Suppl. 5A): 12
  • 2
    Thom DH. Overactive bladder. epidemiology and impact on quality of life. Contemp Ob/Gyn 2000; (Summer Suppl) 614
  • 3
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 7606
  • 4
    Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 32736
  • 5
    Abrams P, Wein AJ. The Impact of Overactive Bladder on Patients and Society, and Current Approaches to Treatment. CME Monograph. Laguna Miguel, CA: The Institute for Medical Studies (IMS), May 2002
  • 6
    Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 (Suppl. 11): S58090
  • 7
    Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (Suppl. 11): S5749
  • 8
    Wagner TH, Hu TW, Bentkover J et al. Health-related consequences of overactive bladder. Am J Manag Care 2002; 8 (Suppl. 19): S598607
  • 9
    Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 30310
  • 10
    Chapple CR. Randomized, double-blind comparison of once-daily solifenacin succinate versus placebo or tolterodine in patients with overactive bladder (OAB). Can J Urol 2003; 10: 1967, A29
  • 11
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 2003; 61: 3749
  • 12
    Kelleher C. Quality of life and urinary incontinence. Baillière's Best Pract Res Clin Obstet Gynaecol 2000; 14: 36379
  • 13
    Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83: 58390
  • 14
    Donovan JL, Badia X, Corcos J et al. Symptom and quality of life assessment. In AbramsP, CardozoL, KhouryS, WeinA eds, Incontinence, 2nd edn. Plymouth: UK Health Publication Ltd, 2002: 267316
  • 15
    Diokno A, Sand P, Labasky R et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002; 34: 439
  • 16
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 13749
  • 17
    Reese PR, Pleil AM, Okano GJ, Kelleher CJ. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003; 12: 42742
  • 18
    Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S61630
  • 19
    Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: in press
  • 20
    Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 3346
  • 21
    Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57: 104450